Supply High Purity Bivalirudin Tfa, Bivalirudin Trifluoroacetate CAS 128270-70-1

Chemically, it is a synthetic congener of the naturally occurring drug hirudin 

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor ofthrombin. It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation.Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.
 

Chemically, it is a synthetic congener of the naturally occurring drug hirudin 

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor ofthrombin. It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation.Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.